Pfizer Inc.’s
PFE,
COVID-19 antiviral Paxlovid brought in $7.5 billion in revenue in the 3rd quarter of the year, towards a FactSet consensus of $7.6 billion. The drug firm also reiterated direction for Paxlovid revenues in 2022, indicating it continue to expects $22 billion in product sales for the yr. The FactSet consensus is $22.5 billion. Pfizer’s inventory has declined 21.1% so significantly this 12 months, although the S&P 500
SPX,
has declined 18.7%.